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Resumo
A função dos laboratórios clínicos é fornecer informa-
ções para decisões médicas no tratamento de doentes. 
Essa informação deve ser tão correta quanto possível, 
e o erro associado limitado a valores aceitáveis tendo 
em conta o uso médico pretendido. O estabelecimen-
to de limites de erro ou especificações de qualidade 
analítica baseia-se na hierarquia de consenso definida 
em Estocolmo (1999). Os laboratórios devem ter como 
meta a definição de especificações a partir de modelos 
mais elevados na hierarquia, sempre que existam da-
dos disponíveis, e o desempenho atual dos métodos o 
permita. A qualidade dos processos de medição pode 
ser avaliada através da métrica Sigma.
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AbstRAct
Clinical laboratories work to provide information for 
medical decisions on patient management. That infor-
mation should be as correct as possible, and the as-
sociated error limited to a certain amount that is toler-
able for medical purposes. A consensus hierarchy of 
models has been established in Stockholm (1999) to 
define such allowable error limits or analytical qual-
ity specifications. Laboratories should aim for higher 
models in hierarchy whenever data is available, and 
current method performance allows achieving the 
goal. Sigma-metrics can be used to assess the quality 
of measurement procedures.
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IntRoductIon
The current practice of Quality Control in laborato-ries has significantly changed in the past decade, 
and far are the days when only the so called Westgard 
Rules (1) were used as criteria to judge analytical runs 
and detect out of control events and methods instabil-
ity. Today, it is important that laboratory professionals 
have up to date skills, and comprehend their impor-
tance in limiting analytical error and what boundaries 
should be established for unacceptable results based 
on method performance. The utmost priority of labo-
ratories is to use the best samples to produce the most 
correct results with a limited amount of error. 
LImItIng AnALytIcAL eRRoR
Great attention is being paid to Quality and Safety 
issues in healthcare (2), either by the regulatory bodies 
or the public opinion, and healthcare professionals, in 
particular laboratory personnel should be aware of that 
(3). Medical decisions often rely on laboratory tests 
information in about two-thirds and three-quarters of 
the cases (4), and because a fraction of diagnostic er-
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rors still comes from laboratory testing (5) every effort 
to reduce them is worthwhile.
Two studies from Plebani and Carraro (6, 7) in a 
stat laboratory from Padua, Italy, have shown that in 
the total testing process the errors are more prone to 
occur in the pre-analytical phase (~65%), being fol-
lowed by the post-analytical (~20%) and analytical 
phase (~15%). Strikingly, 73% of those were prevent-
able, leaving room for improvement in laboratory er-
ror management. 
Although currently the lowest error percentage lies 
on the analytical phase, we must be aware that the as-
sessment of those errors is more difficult, and in in-
stances somewhat neglected by professionals. Indeed, 
the International Federation of Clinical Chemistry 
(IFCC) Working Group on “Laboratory Errors and Pa-
tient Safety” developed a series of Quality Indicators 
(QI’s) and specifications for the laboratory total test-
ing process, and those for the analytical phase were 
the least standardized at first (8), but that model has 
evolved to include seven QI’s (9), from which inde-
pendent quality specifications can be derived.
Having that in mind, we must also highlight that 
the Clinical Laboratory is one of the leading health ser-
vices in addressing Quality issues (10), and the industry 
has greatly contributed with improved instruments and 
technology, that limits result variation by reducing hu-
man tasks and associated errors, and now tend to meet 
the highest performance standards on allowable bias (or 
inaccuracy), imprecision and total error (11).
Nowadays, Quality of care can be intended as “the 
degree to which health services for individuals and 
populations increase the likelihood of desired health 
outcomes, and are consistent with current professional 
knowledge, meeting the expectations of healthcare us-
ers” (12). So, being the focus on the client or user, 
the requirements (patient and medical ones) should be 
determined by the laboratory (13), and a normalized 
process based on a management system should be in 
place in order to consistently achieve the desired re-
sults (14).
WhAt ALLoWAbLe eRRoR LImIts?
The Internal Quality Control process, which is 
time and skilful demanding, and staff training is a key 
factor to success due to the amount of tests performed, 
is the moment where the quality that is required (nu-
merical analytical quality specification – mostly de-
fined as a %TEa – Allowable Total Error) is usually 
determined, and that ultimately guides the establish-
ment of a statistical quality control procedure (number 
of measurements and control rules) (4). In general, 
TEa sets a limit for both the imprecision (random er-
ror) and bias (systematic error) that are tolerable in 
a single measurement or single test result (4). It can 
Table 1 – Stockholm Consensus hierarchy of models to set analytical quality specifications. 
Level Model Source examples 
1. Evaluation of the effect of analytical performance on clinical outcomes in specific clinical situations Diabetes Control and Complications 
Trial – DCCT
2. Evaluation of the effect of analytical performance on clinical decisions in general
     2.A      Data based on the components of biological variation Biological variation database
     2.B      Data based on analysis of clinicians opinions Surveys on patient treatment by doctors
3. Published professional recommendations
     3.A      From national and international expert bodies NCEPa; ADAb; NACBc
     3.B      From expert local groups or individuals Best practice, good laboratory practice
4. Performance goals
     4.A       Set by Regulatory bodies CLIAd – USA, Rilibäke – Germany 
     4.B       Set by Quality Assessment (EQA) schemes NEQASf, RIQASg, RCPAh
5. Goals based on the current state of the art
     5.A      As demonstrated by data from EQA or Proficiency Testing Schemes MQS Spain
i,                 
Unity  Inter-laboratory Program
     5.B      As found in current publications on methodology Evaluation of methods 
aNational Cholesterol Education Program; bAmerican Diabetes Association; National Academy of Clinical Biochemistryc; dClinical Laboratory Improvement Am-
mendment; eGuidelines (“Rili”) of the German Federal Medical Council (BÄK); fUnited Kingdom National External Quality Assessment Service; gRandox Inter-
national Quality Assessment Scheme; hRoyal College of Pathologists of Australasia; iMinimum quality specifications.
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also be viewed as the magnitude of error that causes a 
result to be considered incorrect or unreliable (14).  
These analytical quality specifications or analyti-
cal goals as usually named (15), are to be set based 
on the “Stockholm Consensus Hierarchy of models” 
(Table 1) established in the 1999 Stockholm Consen-
sus Conference on Quality Specifications in Labora-
tory Medicine (16).
The hierarchy recommends that higher level mod-
els should be preferred to those at lower levels, pro-
viding that goals are available and appropriate to a 
specific analyte (15). These models can be split into 
different approaches (17), such as:
1. Clinical-driven goals – This means that the ac-
tual clinicians behavior using test results should 
be studied, to derive the size of an analytical er-
ror (clinical decision interval) that could change 
a medical decision on a specific therapy (i. e. 
Diabetes Control);
2. Biology-driven goals – This means ignoring cur-
rent method performance, but establishing how 
good test methods performance should be, based 
on within and between-subject biologic varia-
tion;
3. Consensus-driven goals – This means establishing 
a goal that the majority of labs and methods can 
achieve, based on current method performance.
In current practice, laboratories should aim first 
at consensus goals, which are best attained, though 
less demanding, but mandatory in some countries (i.e. 
CLIA – USA, RILIBÄK – Germany) for Accredita-
tion purposes, and then establish more demanding 
ones (in general biology and clinical use goals) if they 
are known and documented (17, 18) as shown in the 
examples of Table 2. Apart from %TEa, concentration 
based limits with different specifications given at dif-
ferent medical decision levels, and imprecision based 
limits (i.e. 3SD) specifications can also be set. 
In Czech Republic EQA program Friedecky et al 
(19) found that 98% of the labs could meet Rilibäk 
and SEKK (Czech Republic) acceptance limits, 87% 
the CLIA limits, 72% the RCPA limits, and only 22% 
the biological variation limits.
Despite the above results, the biological varia-
tion model (Level 2A) is now widely used (20) and 
considered the best for practical purposes (monitor-
ing individual patients, and diagnosis using reference 
intervals) (21), and the database that is updated every 
two years, currently comprises more than 320 analytes 
(18, 22). Due to the large or small biological varia-
tion of some analytes, the desirable analytical goal can 
be easily attained (CPK) or hardly met (Sodium) with 
current technology, so optimum and minimum speci-
fications (Table 2) can also be defined by laboratories 
for bias, imprecision and TEa (22), based on the for-
mulas proposed by Fraser et al (23). 
In Spain, EQA results have shown that the BV total 
error specification for albumin, HDL-cholesterol, so-
dium and calcium was attained by close to 10%, 20%, 
50% and 70% of labs respectively (22), somewhat de-
mystifying its unreachable character. It is also of note 
that analytical goals for levels 3 and 4 of the hierarchy 
are also being set by the organizations involved based 
on Level 2A (15, 24).
PeRfoRmAnce evALuAtIon
The way labs attain the analytical goals of a spe-
cific analyte will characterize its performance. One 
way is by estimating the Total Error of the method and 
verifying that it is smaller than the defined require-
ment as TEa (25):
Table 2 – Analytical quality specifications for cholesterol, glucose, creatine kinase and sodium.
Specification Source Analytical Quality Specification
Cholesterol Glucose Creatine kinase Sodium
Rilibäk (Germany) 13% 15% 20% 5%
Minimum QS (Spain) 11% 11% 24% 5%
BV Minimum goal 12.73% 10.78% 45.5% 1.33%
CLIA (USA) 10% 10% ± 30% ± 4 mmol/L
BV Desirable goal 8.5% 7.2% ± 30.3% 0.9%
RCPA (Australia) 6% 8% 12% ± 3 mmol/L < 150 mmol/L 
± 2% > 150 mmol/L
BV Optimum goal 4.24% 3.60% 15.2% 0.45%
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 TE95%CI = Bias% + (1.65xCV%) < TEa
Then, the lab can also monitor method improve-
ment by calculating TE budget percent:
 [TE / TEa] x 100
Another approach is Sigma-metrics (six sigma an-
alytical performance) which is calculated as follows 
(4): 
 σ = (%TEa – %BIASa)/ %CVa
The resulting Sigma value, characterizes method 
performance in terms of the number of standard de-
viations or sigmas that fit within the tolerance limit 
or quality requirement of a test, and also gives us a 
notion of the number of defects (possible errors) per 
million tests we are delivering in the analytical pro-
cess (26). 
As shown in Table 3 the higher the sigma level, 
the better the test performance, being 3-sigma quality 
usually recommended as the minimum for a produc-
tion process (26), but in many cases this are problem-
atic tests requiring maximum statistical quality control 
procedures (13).
The achieved performance is greatly influenced by 
the defined tolerance limit (TEa), and here there’s a 
need for harmonization of practice since significant 
differences exist between and within countries (14), 
making comparison of performance data unreliable. 
Sigma performance is also different at different medi-
cal decision levels, being usually better at higher con-
centrations, so at lower levels is where we should find 
space for method improvement. 
By knowing the estimates of method bias and pre-
cision and having defined TEa, the most appropriate 
statistical quality control procedure (number of mea-
surements and control rules) can be selected that pro-
vides at least 90% probability to detect clinically sig-
nificant errors, and a maximum of 5% chance of false 
rejections (4). Not being the scope of this article to ex-
plain such a process, a general picture of QC frequency 
based on Sigma value has been proposed (13):
>6 σ   (excellent tests) – evaluate with one QC per 
day (alternating levels between days) and a 1:3.5 
s rule.
4s–6 σ (suited for purpose) – evaluate with two 
levels of QC per day and the 1:2.5 s rule.
3s–4 σ (poor performers) – use a combination of 
rules with two levels of QC twice per day.
<3 σ (problematic tests) – maximum QC, three lev-
els, three times a day. Consider testing specimens 
in duplicate.
Several software tools like UnityRealTime® (Bio-
Rad, Hercules, USA), Accusera 24.7® (Randox, Crum-
lin, UK), are now in the market to assist the Clinical 
Laboratory in Quality control design and evaluation. 
These tools which are part of inter-laboratory pro-
grams allow real-time peer comparison of QC data 
from thousand of Labs around the world, faster detec-
tion of errors in the test systems and increased confi-
dence on selected comparison targets. It is also a step 
for meeting the requirements of medical laboratories 
accreditation, which currently is only mandatory in 
France at the European level (14).      
Table 3 – Sigma conversion chart.
Sigma Level Defects/million tests % Defect Sigma Level Defects/million tests % Defect
6 3 0,00034% 3 66,807 6,7%
5.5 32 0,0032% 2.5 158,655 15,86%
5 233 0,023% 2.0 308,538 31%
4.5 1,350 0,135% 1.5 500,000 50%
4 6,210 0,62% 1.0 691,462 69%
3.5 22,750 2,275% 0.5 841,345 84.1%
fInAL consIdeRAtIons
Every lab result always includes error. Our job as 
laboratory professionals is to limit that error to a toler-
able amount that is not clinically significant for patient 
management. Strictly adherence to good laboratory 
practices, from specimen collection, calibration pro-
cedures, planning and implementation of proper inter-
nal quality control for each analyte (including defini-
tion of analytical quality specifications), timely and 
accurate result delivery will certainly impact on the 
magnitude of those errors, and provide doctors best 
clinical decisions and patient improvement.
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